throbber
I EDIC
`
`LIJAR.19.96
`
`f VOLUME 10 NUMBER3
`W1 AL375
`tr.
`1996
`NO.3 (cid:9)
`9 51 11 ------- SEQ: 5R0057930
`- 1
`(cid:9) ALIMENTARY PHARMACOLOGY
`07/01/96
`AND THERAPEUTIC: (cid:9)
`
`li
`
`CODEN APTHEN ISSN 0269-2813
`
`,
`
`40)
`
`ry
`411 C
`Pe
`
`tics
`
`fkilkoiloituipotst1 jjoitorw ti Atoctikti
`(kW; Alticimuj (cid:9)
`wAv;)},, iNt.w.7109)
`
`Blackwell
`Science
`
`Wyk EtRITOcgiAL
`LIBRARY OF
`MEDICINE
`
`this
`
`Lsws.
`
`Ex. 1083 - Page 1
`
`

`

`Alimentary Pharmacology & Therapeutics
`
`Editors
`Professor R E Pounder London
`Professor W L Peterson Dallas
`
`International Editorial Board
`Chairman: Professor M J S Longman
`Birmingham
`Dr K D Bardhan Rotherham
`Professor G Bianchi Porro Milan
`Dr J Cabin London
`Professor M Camilleri Rochester
`Professor V S Chadwick Wellington,
`NZ
`Professor M Classen Munchen
`Professor H G Dammann Haniburg
`Dr G Delle Fave Rome
`Professor W Domschke Minister
`Professor M J G Farthing London
`Professor M Feldman Dallas
`Dr A G Fraser Auckland
`Professor D Y Graham Houston
`Professor N D Granger Shreveport
`
`Professor N J Greenberger
`Kansas City
`Professor F Halter Bern
`Professor S B Hanauer Chicago
`Professor C J Hawkey Nottingham
`Dr R C Heading Edinburgh
`Dr R V Heatley Leeds
`Professor H J F Hodgson
`Hammersmith
`Professor R H Hunt Hamilton
`Dr R T Jensen Bethesda
`Professor K Kawai Kyoto City
`Professor G J Krejs Graz
`Dr L A Laine Los Angeles
`Professor S K Lam Hong Kong
`Professor R Lambert Lyon
`Professor CB H W Lamers Leiden
`Professor J E Lennard-Jones London
`Dr K F McCarthur Dallas
`Professor K E L McColl Glasgow
`Professor W C Maddrey Dallas
`Professor J-R Malagelada Barcelona
`
`Professor M Mignon Paris
`Professor T C Northfield London
`Professor S Okabe Kyoto City
`Professor C O'Morain Dublin
`Professor S F Phillips Rochester
`Professor L Powell Queensland
`Dr D S Rampton London
`Professor J Rask-Madsen Copenhagen
`Professor J M Rhodes Liverpool
`Professor M G Robinson Oklahoma
`City
`Professor J Rodes Barcelona
`Professor G Sachs Los Angeles
`Professor K F Sewing Hanover
`Professor R A Smallwood Victoria
`Professor C Takemoto Ube City
`Dr N J Talley Australia
`Professor L A Turnberg Salford
`Professor G N Tytgat Amsterdam
`Professor J L Wallace Alberta
`Professor J H Walsh Los Angeles
`Dr R P Walt Birmingham
`
`Editorial Assistant UK: Doris Elliott, Tel,: +44 (0)171 830 2243; Fax: +44 (0)171 431 5261.
`Editorial Assistant USA: Julie Enright, Tel.: +1 214 371 6441 ; Fax: +1 214 372 7986.
`
`Production Editor: Howard Waller, Blackwell Science Ltd, Osney Mead, Oxford 0X2 OEL, UK.
`Tel: +44 (0)1865 206120: Fax: +44 (0)1865 200918; E-mail: howard.waller@blacksci.co.uk
`
`Aims and editorial policy
`Alimentary Pharmacology 4'7. Therapeutics is an international journal
`concerned with the effects of drugs on the gastrointestinal and hepato-
`biliary systems, particularly with relevance to clinical practice. The
`Journal accepts original papers concerned with all aspects of basic and
`clinical pharmacology, pharmacokinetics and the therapeutic use of
`drugs in the alimentary tract including the liver, gall-bladder and
`pancreas.
`The Journal is included in the major information retrieval systems,
`including Index Medicus and Medline, the cimu a, index, CABS Science
`Citation Index, Current Contents—Life Sciences, Excerpta Medica and
`Current Opinion in Gastroenterology.
`
`Subscriptions
`Alimentary Pharmacology CT Therapeutics is published six limes in 1996.
`Subscription prices for 1996 are: Institutional 11165.00 (Europe),
`£165.00 (Overseas), $265.00 (North America). Individual £49.50
`(Europe), £49.50 (Overseas), $79.00 (North America). Subscribers in
`Canada must add 7% to the subscription price, to allow for GST.
`Subscribers in Europe must quote their VAT registration number or state
`that they are not registered. Subscribers in the following countries who
`are not VAT-registered must add VAT at the appropriate rate: Belgium
`(6% TVA/I3TW), France (2.17 TVA), Germany (7% MWST), Spain (4%
`IVA), the Netherlands (6% B'I'W). Orders for current subscriptions and
`back issues should be sent to Blackwell Science Ltd, Journal
`Subscriptions, PO Box 88, Oxford 0X2 ONE, UK. Tel.: +44 (0)1865
`206180 or 206038, Fax: +44 (0)1865 206219, E-mail:
`journals.cs@blacksci.co.uk.
`
`* Second class postage paid at Rahway. NI. Postmaster, send address changes to
`Alimentary Pharmacology Therapeutics c/o Mercury Airfreight International Inc.,
`2 32 3 EU Randoll Avenue, Avenel, NJ 0700 1 , USA.
`
`Despatch
`Alimentary Pharmacology & Therapeutics is despatched within the UK by
`2nd class post, within Europe by air mail, and to other continents by
`various forms of air-speeded delivery: to the US by air freight for for-
`warding by second class post,* to India by air freight for guaranteed local
`delivery, and to all other countries by accelerated surface post. Add to
`the cost of regular subscription 1124.00/$36.00 for air mail delivery
`outside Europe.
`
`Business correspondence
`All business correspondence, including orders for further offprints and
`advertising space, should be addressed to Alimentary Pharmacology
`Therapeutics, Blackwell Science Ltd, Osney Mead, Oxford 0X2 OEL, UK.
`Tel.: +44 (0)1865 206206: Fax: +44 (0)1865 721205; Telex: 83355
`Medbok G.
`
`Copyright and photocopying
`© 1996 Blackwell Science Ltd. Authorization to photocopy items for
`internal or personal use, or the internal or personal use of specific clients,
`is granted by Blackwell Science Ltd for libraries and other users registered
`with the Copyright Clearance Center (CCC) Transactional Reporting
`Service, provided that the base fee of $11.50 per copy is paid directly to :
`CCC, 222 Rosewood Drive, Suite 910, Danvers, MA (11973, USA. This
`consent does not extend to other kinds of copying, such as copying for
`general distribution, for advertising or promotional purposes, for creating
`new collective works or for resale. Special requests should be addressed to
`the Editor. ISSN 0269-281 3/96/$1 1.50.
`
`Paper
`The publisher's policy is to use acid-free permanent paper, to the draft
`standard ISO/DIS/9706, made from sustainable forest using chlorine-free
`pulp. The paper used in this journal has an ECO-CHECK 4-star rating.
`
`
`
`It (cid:9) Yts'a• i=1 `.'
`
`Ex. 1083 - Page 2
`
`

`

`Alimentary
`Pharmacology
`& Therapeutics
`
`VOLUME 10 NUMBER 3 JUNE 1996
`
`Contents
`
`217 Letter from the Editors. R. E. POIINDER &
`W. L. PETERSON
`219 Review article: Renal circulatory changes in
`cirrhosis — pathogenesis and therapeutic prospects.
`E. H. FORREST, R. JALAN & P. C. HAYES
`233 Clinical economics review: gastrointestinal disease
`in primary care. R.11. JONES
`241 Ranitidine bismuth citrate: a novel anti-ulcer
`agent with different physico-chemical
`characteristics and improved biological activity to
`a bismuth citrate—ranitidine admixture.
`A. A. McCOLM, A. McLAREN, G. KLINKERT,
`M. R. FRANCIS, P. C. CONNOLLY, C. J. GRINHAM,
`C. J. CAMPBELL, S. SELWAY & R. WILLIAMSON
`251 Ranitidine bismuth citrate plus clarithromycin is
`effective for healing duodenal ulcers, eradicating
`H. pylori and reducing ulcer recurrence.
`W. L. PETERSON, A. A. CIOCIOLA, D. L. SYKES,
`D. J. McSORLEY, D. D. WEBB & THE RBC
`H. PYLORI STUDY GROUP
`263 Omeprazole—amoxycillin versus omeprazole—
`amoxycillin—clarithromycin in the eradication of
`Helicobacter pylori. J. C. DELCHIER, I. ELAMINE,
`D. GOLDFAIN, S. CHAUSSADE, P. BARTFIELEMY
`& J. P. IDSTROM
`269 Prospective evaluation of the macrolide antibiotic
`dirithromycin for the treatment of Helicobacter
`pylori. L. LAINE, C. STEIN, F. GARCIA,
`M. TRUJILLO & R. ESTRADA
`275 Comparison of two low-dose one-week triple therapy
`regimens with and without metronidazole for cure of
`H. pylori infection. B. H. JAUP & A. NORRBY
`279 A seven-day Helicobacter pylori treatment regimen
`using clarithromycin, omeprazole and tripotassium
`dicitrato bismuthate. M. J. WELDON,
`A. BROADBENT, S. CHAMBERS, R. MISTRY,
`L. RANGANATH & S. R. GOULD
`
`A
`1308 (4-61 137
`11(,
`03/26/9/ (cid:9)
`
`MRB
`
`Printed in Great Britain by the University Press, Camber o,at a i I
`
`Suaien 27 7 (cid:9)
`
`Laws
`
`285 Low-dose omeprazole plus clarithromycin and either
`tinidazole or amoxycillin for Helicobacter pylori
`infection. A. TURSI, G. CAMMAROTA,
`M. MONTALTO, A. PAPA, G. VENETO, L. CUOCO,
`F. TRUA, G. BRANCA, G. FEDELI & G. GASBARRINI
`289 Effect of proton pump inhibitors on the detection of
`Helicobacter pylori in gastric biopsies. W. DICKEY,
`B. D. KENNY & J. B. McCONNELL
`295 Pharmacokinetic and pharmacodynamic
`interactions between omeprazole arid amoxycillin
`in Helicobacter pylori-positive healthy subjects.
`W. POMMERIEN, M. BRAUN, J.-P. IDSTROM,
`M. WRANGSTADH & W. LONDONG
`303 Dose—response of omeprazole combined with
`amoxycillin on duodenal ulcer healing and
`eradication of Helicobacter pylori.
`W. POMMERIEN, V. SCHULTZE, B. BRADEN,
`B. LEMBCKE, M. WRANGSTADH & W. LONDONG
`309 Methotrexate for the treatment of refractory
`Crohn's disease. M. LEMANN, C. CHAMIOT-
`PRIEUR, B. MESNARD, M. HALPHEN, B. MESSING,
`J.-C. RAMBAUD, J.-P. GENDRE, J.-F. COLOMBEL
`& R. MODIGLIANI
`315 Picotamide inhibition of excess in vitro
`thromboxane B2 release by colorectal mucosa in
`inflammatory bowel disease. C. E. COLLINS,
`M. J. BENSON, W. R. BURNHAM
`& D. S. RAMPTON
`321 Strengths and limitations of the Crohn's disease
`activity index, revealed by an objective gut lavage
`test of gastrointestinal protein loss. S. ACCIUFFI,
`S. GHOSH & A. FERGUSON
`327 Distribution of mesalazine enemas in active arid
`quiescent ulcerative colitis. A. A. VAN
`BODEGRAVEN, R. 0. BOER, J. LOURENS,
`H. A. R. E. TUYNMAN & J. W. SINDRAM
`
`b
`
`Blackwell
`Science (cid:9)
`
`Continued on inside back cover
`
`0269-2813 (cid:9)
`
`99606 )10 : 3; 1-N
`
`Ex. 1083 - Page 3
`
`

`

`COOtinued from back cover
`
`333 How accurate is the determination of blood in
`gastric juice? Comparison of peroxidase and
`porphyrin methods. K. L. WOODS, C. KEIFE
`& D. Y. GRAHAM
`339 The role of acid in the pathogenesis of
`indomethacin-induced gastric antral ulcers in the
`rat. N. M. CLAYTON, I. OAKLEY, L. V. WILLIAMS
`& M. A. TREVETHICK
`347 High-dose ranitidine for the prevention of
`recurrent peptic ulcer disease in rheumatoid
`arthritis patients taking NSAIDs. S. TEN WOLDE,
`B. A. C. DIJKMANS, M. JANSSEN, J. HERMANS
`& C. B. FL W. LAMERS
`353 Diagnostic interpretation of the 24-hour
`intragastric pH-mctry using a pattern recognition
`method. B. HUNYADY, I. JURICSKAY,
`F. PAKODI, Cs. HORVATH & Gy. MOZSIK
`359 Twenty-four-hour intragastric pH profiles and
`pharmacokinctics following single and repeated
`oral administration of the proton pump inhibitor
`pantoprazole in comparison to omeprazole.
`M. HARTMANN, U. THEIE, R. HUBER,
`R. LUHMANN, H. BLIESATH, W. WURST
`& P. W. LUCKER
`367 The effects of omeprazole 20 and 40 mg twice daily
`on intragastric acidity in duodenal ulcer patients.
`V. SAVARINO, G. S. MELA, P. ZENTILIN,
`M. R. MELE, S. VIGNERI, C. MANSI & G. CELLE
`373 Ranitidine 300 mg twice daily and 150 mg four-
`times daily are effective in healing erosive
`oesophagitis. M. T. SILVER, R. H. MURDOCK Jai,
`B. B. MORRILL & S. 0. SUE
`3S 1 A trial of lansoprazole in refractory gastric ulcer.
`C. J. VAN RENSBURG, J. A. LOUW, A. H. GIRDWOOD,
`A. E. SIMJEE & I. N. MARKS
`
`387 The management of refractory gastric ulcer using
`H,-receptor antagonists. G. S. RAJU,
`K. D. BARDHAN, C. ROYSTON & J. BERESFORD
`397 Efficacy and tolerability of pantoprazole 40 mg
`versus 80 mg in patients with reflux oesophagitis.
`C. J. VAN RENSBURG, P. J. HONIBALL,
`H. DE K. GRUNDLING, J. H. VAN ZYL, S. K. SPIES,
`F. P. ELOPE, A. E. SIMJEE, I. SEGAL, J. F. BOTHA,
`A. K. CARIEM, I. N. MARKS, I. THERON
`& T. D. BETHKE
`403 Symptomatic improvement with one-year
`cisapride treatment in neuropathic chronic
`intestinal dysmotility. M. CAMILLERI, R. K. BALM
`& A. R. ZINSMEISTER
`411 Effect of dexloxiglumide and spiroglumide, two
`new CCK-receptor antagonists, on gastric
`emptying and secretion in the rat: evaluation of
`their receptor selectivity in vivo.
`C. SCARPIGNATO, I. KISFALVI, M. D'AMATO
`& G. VARGA
`421 Effect of erythromycin on human biliary motility.
`T. WEHRMANN, C. PFELTZER & W. F. CASPARY
`427 Gastric emptying of pancreatin granules and
`dietary lipids in pancreatic insufficiency.
`P. NORREGAARD, J. LYSGAARD MADSEN,
`S. LARSEN & H. WORNING
`433 Pancreatin preparations used in the treatment of
`cystic fibrosis—lipase content and in vitro release.
`M. P. WALTERS & J. M. LITTLEWOOD
`441 Sucralfate gel versus placebo in patients with non-
`erosive gastro-oesophageal reflux disease.
`B. SIMON, G.-P. RAVELLI & H. COFFIN
`447 Letters to the Editors. V. SAVARINO, G. S. MELA
`& S. VIGNERI and J. HENDEL, L. HENDEL
`& S. AGGESTRUP
`
`al
`
`at • -
`
`i = - tL 3ws
`
`Ex. 1083 - Page 4
`
`

`

`Aliment Pharmacol Ther 1996: 10: 309-314.
`
`Methotrexate for the treatment of refractory Crohn's disease
`
`M. LEMANNt, C. CHAMIOT-PRIEURt, B. MESNARDt, M. HALPHEN§, B. MESSING§,
`J.-C. RAMBAUD§, J.-P. GENDRE1F, J.-F. COLOMBEL* & R. MODIGLIANIt
`Departments of Gastroenterology, t Hopital Saint-Louis, Paris, HOPital Claude Huriez, Lille, § HOpital Saint-Lazare and
`HOpital Rothschild, Paris, Prance
`
`Accepted for publication 3 January 1996
`
`SUMMARY
`
`Background: Previous studies suggested that
`methotrexate has beneficial effects in patients with
`Crohn's disease. We report our experience with this
`agent in patients with chronic active Crohn's disease
`who previously failed to improve with conventional
`treatment, including azathioprine in most cases.
`Methods: Between June 1988 and June 1992, 39
`patients with refractory Crohn's disease were treated
`with methotrexate. In patients with active disease,
`clinical remission was defined by a Harvey—Bradshaw
`index of less than 4. For patients also taking
`corticosteroids, the dates of remission and complete
`steroid withdrawal were recorded. For patients who
`
`achieved clinical remission, and those in clinical
`remission when methotrexate was started, the relapse
`rate on methotrexate therapy was noted.
`Results: In the 37 patients with active disease at
`methotrexate initiation, the probability of remission
`was 72% at 3 months. The probability of remission
`and steroid withdrawal was 42% at 12 months. In
`patients on clinical remission, the probability of relapse
`on methotrexate was 58% at 12 months. Twenty-two
`patients experienced side-effects, but these only
`warranted methotrexate discontinuation in four cases.
`Conclusions: Methotrexate appears effective in most
`patients with refractory Crohn's disease and its short-
`term toxicity is acceptable, but the long-term benefit
`seems more limited.
`
`INTRODUCTION
`
`Methotrexate is one of the oldest cytototoxic drugs which
`acts as a potent inhibitor of folic acid, an essential
`cofactor for de novo purine synthesis. Because of its anti-
`inflammatory and immunosuppressant properties, it has
`been used at low doses to treat various non-neoplastic
`immunologically mediated diseases, including psoriasis,
`rheumatoid arthritis and polymyositis/dermatomyositis.
`It was also recently proposed for the treatment of
`inflammatory bowel disease.' The results of preliminary
`studies suggest that methotrexate may have beneficial
`effects in patients with refractory chronic ulcerative
`colitis or Crohn's disease.1-5 A recent placebo-controlled
`study in patients who had chronically active Crohn's
`
`Correspondence to: Dr M. Le771111111, Service de Gastroenterologie, Hopital
`Saint-Louis, 1 Avenue Claude Vellefaux, F75010, Paris, France.
`
`disease demonstrated that intramuscular methotrexate
`(25 mg once a week) for 16 weeks was more effective
`than placebo in improving symptoms and reducing
`requirements for steroids.'
`We report here on our experience with methotrexate in
`the management of patients with chronic active Crohn's
`disease who previously failed to improve with conven-
`tional treatment, including azathioprine in most cases.
`
`PATIENTS AND METHODS
`
`Patient population
`
`Between June 1988 and June 1992, 39 patients with
`Crohn's disease (23 females and 16 males) were treated
`with methotrexate in the four French hospital centres
`participating in this study. The 39 patients represented
`3% of the patients with Crohn's disease seen in these
`
`© 1996 Blackwell Science Ltd
`
`309
`
`Thia rata ial as ::sia3
`
`Laws
`
`Ex. 1083 - Page 5
`
`

`

`310 (cid:9) M. LEMANN et al.
`
`centres during the same period. Their charts were all
`reviewed by the same physician (C.C-P.). Diagnosis of
`Crohn's disease was based on clinical, endoscopic,
`radiological and histological criteria.' The mean age of
`the patients was 29.2 ± 8.4 years (range, 17-43 years).
`The mean duration of disease was 6.4 + 3.7 years. One
`patient had jejunitis (2 %), two had ileitis (5%), 22 had
`ileocolitis (56%) and 14 had colitis (36%). Twelve
`patients (31 %) had also had perianal lesions, but only
`four of them had active lesions at the time of metho-
`trexate initiation. Twenty-two patients (56%) had under-
`gone prior small bowel, ileocolonic and colonic resection
`(n = 11, 8 and 3, respectively). All patients had been
`treated with corticosteroids for a mean period of 7.3 ± 4.7
`months, but, at the time of methotrexate initiation, only
`24 patients (62 %) were still taking prednisolone at a
`mean daily dose of 20.5 ± 21.0 mg (range, 5-
`70 mg/day). Fifteen of them were dependent on
`steroids and nine were resistant to steroids ; six of these
`nine were having concomitant parenteral nutrition
`(n = 3) or enteral nutrition (n = 3) at the time of
`methotrexate initiation. Fifteen patients (38%) were not
`given corticosteroids when methotrexate started, in order
`to avoid a new course of steroids. Thirty-six patients
`(92 %) had previously taken azathioprine, but were no
`longer on this therapy because of drug intolerance
`(n = 16) or clinical failure (n = 20). All the patients had
`been previously treated with sulphasalazine or had
`mesalazine treatment during the course of their disease,
`and some of them had been treated with metronidazole,
`but none of them were still taking these drugs at the time
`of methotrexate initiation.
`
`Methotrexate therapy
`
`The planned regimen was to give patients one intra-
`muscular injection of 25 mg methotrexate per week for
`at least 3 months. If improvement was evident by the end
`of that time, the dose was given orally and tapered to a
`minimum of 7.5 mg per week, according to the scheme
`proposed by Kozarek et a1.1 For patients still taking
`corticosteroids when methotrexate was started, an at-
`tempt was made to reduce the daily dose as soon as
`possible, depending on their clinical status.
`
`Evaluation of treatment outcome
`
`Patients were seen regularly and none was lost to
`follow-up. At each visit, clinical status was recorded and
`
`Thit:
`att-
`
`a physical examination performed. Laboratory investi-
`gations included blood cell counts and liver function
`tests. Disease activity was judged according to the
`Harvey—Bradshaw five-item Clinical Activity Index,'
`ranging from 0 (no disease) to 15 (severe disease). In the
`37 patients with active disease at the start of metho-
`trexate (Harvey—Bradshaw index 4), clinical remission
`was defined by a Harvey—Bradshaw index of less than 4.
`Partial response was defined as a decrease in the index
`without clinical remission. For the 24 patients who were
`taking corticosteroids at the start of methotrexate, the
`dates of clinical remission and complete steroid with-
`drawal were also noted. For patients who achieved
`clinical remission on methotrexate, and those who were
`in remission on steroids at the start of methotrexate
`(n = 2), the relapse rate on methotrexate maintenance
`therapy was recorded, as well as in 11 patients who
`stopped the treatment for reasons other than relapse.
`Lastly, the achievement of the specific therapeutic goals
`listed below was also evaluated according to the method
`proposed by Present et al.° and modified by O'Brien et al.1°
`based on the definition of specific therapeutic goals for
`each patient. For the present series, these goals com-
`prised: (a) control of active disease, (b) steroid sparing for
`patients who required more than 10 mg/day of pred-
`nisone when the methotrexate was started (the aim was
`to reduce the dose to less than 10 mg/day), (c) prevention
`of clinical relapse for patients who had achieved complete
`remission, (d) perianal fistula healing and (e) control of
`extraintestinal manifestations.
`
`Statistical analysis
`
`For patients with active disease at the start of metho-
`trexate treatment, the probability of complete remission
`was calculated using the Kaplan—Meier method."
`Follow-up began on the day methotrexate was started
`and continued until clinical remission, until the last
`examination or until the day of methotrexate with-
`drawal. For patients on methotrexate maintenance
`therapy, the probability of relapse was calculated using
`the same method. Follow-up began for them on the day
`of clinical remission, and continued until clinical relapse
`(Harvey—Bradshaw index 4), the last examination or
`the day of methotrexate withdrawal. Probabilities were
`expressed with their 95 % confidence interval (95% CI).
`Quantitative data were expressed as means ± standard
`deviation. The characteristics of the patients who re-
`lapsed were compared with those of the patients who
`
`© 1996 Blackwell Science Ltd, Aliment Pharmacol Ther 10, 309-314
`
`Ex. 1083 - Page 6
`
`

`

`remained on remission, using the x2 test. A P value of less
`than 0.05 was considered significant.
`
`RESULTS
`
`Methotrexate dose and duration
`
`Initially, all patients were given methotrexate as an
`intramuscular injection, at a weekly dose of 25 mg for 36
`of them, and of 20 mg for the remaining three. After 3, 6
`and 12 months of treatment, the average weekly doses of
`methotrexate were 23.0 + 2.1, 17.5 + 7.2 and
`12.5 ± 6.1 mg, respectively, and the proportions of pa-
`tients given methotrexate orally were 3, 69 and 100%,
`respectively. The median duration of methotrexate ther-
`apy was 5.5 months (range, 2 weeks-24 months). Only
`six patients were treated for more than 1 year. Metho-
`trexate therapy was stopped for the following reasons :
`treatment failure in 20 patients, either primarily (n = 4)
`or after an initial improvement (ri = 16), side-effects in
`four patients; other reasons in eight patients.
`
`Clinical response in patients with active disease
`
`Twenty-six of 37 patients with active disease at metho-
`trexate initiation achieved clinical remission. After 1 and
`3 months of treatment, the probabilities of remission
`were 53% (95% CI, 36-69%) and 72% (95% CI,
`57-88 %), respectively (Figure 1). The period required to
`achieve remission ranged from 2 weeks to 6.5 months,
`but most patients who achieved remission did so within
`3 months. Six patients exhibited a partial response. Two
`
`100 -
`90 -
`80 -
`70 -
`60 -
`50 -
`40 -
`30 -
`20 -
`10-
`0 (cid:9)
`
`
`.0
`"(T)) E
`0
`0
`
`.0
`0 a-
`
`2 3 4 5 6 7 8 9 10 11 12
`Months
`
`Patients
`at risk (cid:9)
`37 (cid:9)
`15
`Figure 1. Probability of clinical remission (Harvey—Bradshaw
`index < 4) in 37 Crohn's disease patients with active disease
`when methotrexate started.
`
`7 (cid:9)
`
`6 (cid:9)
`
`3 (cid:9)
`
`2 (cid:9)
`
`0
`
`METHOTREXATE IN CROHN'S DISEASE 311
`
`100 -
`90 -
`80 -
`70
`60
`50
`40
`30
`20 -
`10-
`0 (cid:9)
`
`1 2 3 4 5 6 7 8 9 10 11 12
`Months
`
`24 22 16 8 5 4 1
`
`Patients
`at risk
`Figure 2. Probability of clinical remission and steroid withdrawal
`in 24 Crohn's disease patients taking corticosteroids when
`methotrexate started.
`
`of the five patients considered as failures had surgery :
`one of them underwent colectomy at week 2 because of
`colonic perforation, and the other failed to improve on
`methotrexate and underwent colectomy at month 8.
`Figure 2 shows the probabilities of clinical remission and
`steroid withdrawal for the 24 patients who were taking
`steroids at methotrexate initiation. After 3, 6 and 12
`months on methotrexate, these probabilities were 17%
`(95% CI, 6-25%), 33% (95% CI, 13-53%) and 42%
`(95% CI, 19-67%), respectively.
`
`Relapses in patients on maintenance treatment with
`methotrexate
`
`Twenty-eight patients were treated with methotrexate in
`order to maintain clinical remission. This group included
`the 26 patients who had previously achieved a clinical
`remission on methotrexate, and two patients who were
`in remission on steroids at the start of methotrexate. For
`this group of 28 patients, the probabilities of relapse on
`methotrexate at 3, 6 and 12 months were 13% (95% CI,
`0-27%), 38% (95% CI, 15-62%) and 58% (95% CI,
`30-85%), respectively (Figure 3). For the 10 patients
`who experienced a relapse, the average weekly dose of
`methotrexate at the time of relapse was 14 + 6.4 mg
`(range, 7.5-25 mg) and the drug was administered orally
`in nine of the 10 cases. For the 18 patients who remained
`on clinical remission, the average weekly dose of metho-
`trexate at last follow-up was similar (17.7+ 6.3 mg ;
`range, 7.5-25 mg; P > 0.05) but a smaller proportion
`(11 out of 18) was treated orally (P < 0.01). The average
`daily dose of steroids in patients who had a relapse was
`
`© 1996 Blackwell Science Ltd, Aliment Pharmacol Ther 10, 309-314
`
`This (cid:9)
`att•-•E
`
`z
`
`Ex. 1083 - Page 7
`
`

`

`Table 1. Success rate for achieving specific therapeutic goals
`with methotrexate
`
`Indication for methotrexate (cid:9)
`
`No. of
`No. of (cid:9)
`success
`patients (%)
`
`Control of active disease
`Steroid sparing*
`Prevention of clinical relapse
`Perianal fistula healing (cid:9)
`Control of extraintestinal manifestations
`Totalt
`
`37
`y-) (cid:9)
`28 (cid:9)
`
`93
`
`26 (70)
`15 (68)
`18 (64)
`2 (50)
`1 (50)
`62 (67)
`
`* The goal was to reduce the dose to less than 10 mg predni-
`sone-equivalent per day.
`t Most patients had more than one specific goal.
`
`Side-effects
`
`Table 2 shows the frequency of adverse events encoun-
`tered during methotrexate treatment. Of the 39 patients,
`22 (56%) experienced side-effects, and these effects were
`severe enough in four patients (10%) to warrant dis-
`continuation of the drug. Of note, gastrointestinal symp-
`toms occurred in six patients after they were switched to
`the oral methotrexate. None of the patients experienced
`severe adverse haematological, liver or pulmonary ef-
`fects, or serious infection during methotrexate treatment.
`A liver biopsy was performed in four patients after they
`had received a total dose of 1500 mg of methotrexate.
`Two patients had a normal biopsy, one patient had
`peliosis and one patient had a granulomatous hepatitis.
`
`DISCUSSION
`
`In this work, we report our experience of the use of
`methotrexate in 39 patients with Crohn's disease re-
`sistant to conventional treatment. Before being given
`methotrexate, all patients had been taking steroids ; 24 of
`them (59%) were still doing so and exhibited either
`steroid dependence or resistance when methotrexate
`treatment started. Twenty-two patients (56%) had had
`previous surgery. In 36 patients (92 %), azathioprine had
`been tried but had failed, either because of poor
`intolerance or the absence of improvement.
`Our short-term results are comparable to those reported
`by other authors.'" Clinical improvement was obser-
`ved in 90% of our patients and two-thirds of them
`achieved complete clinical remission within 3 months of
`methotrexate therapy. These rates of improvement are
`
`© 1996 Blackwell Science Ltd, Aliment Pharmacol Ther 10, 309-314
`
`312 (cid:9) M. LNANN et al.
`
`1 2 3 4 5 6 7 8 9 10 11 12
`Months
`
`100 —
`90 —
`80 —
`70 —
`60 —
`50 —
`40 —
`30 —
`20 —
`10 —
`0
`
`Probability of relapse (%)
`
`Patients 28 26 15 10 7 5 4
`at risk
`Figure 3. Probability of relapse (Harvey—Bradshaw index ,..>... 4) in
`28 Crohn's disease patients on maintenance treatment with
`methotrexate, including 26 patients who previously experienced
`a clinical remission on methotrexate and two patients who were
`in remission when methotrexate started.
`
`1 2 (cid:9)
`
`4 5 (cid:9)66 7 8 9 10 11 (cid:9)12
`Months
`
`100 -
`90 -
`80 -
`70 -
`60
`50 -
`40 -
`30 -
`20 -
`10-
`0 (cid:9)
`
`
`Probability of relapse (%)
`
`5 (cid:9)
`
`2 (cid:9)
`
`1 (cid:9)
`
`Patients
`11 (cid:9)
`at risk
`Figure 4. Probability of relapse (Harvey—Bradshaw index ?.. 4) in
`11 Crohn's disease patients who stopped methotrexate for
`reasons other than failure.
`
`1 (cid:9)
`
`1
`
`8.3 ± 9.4 mg (range, 0-30 mg), compared with
`5.6 + 10.4 mg (range, 0-40 mg) in patients still in
`remission at their last visit (P > 0.05). Eleven of the
`18 patients maintained in complete remission stopped
`methotrexate for reasons other than relapse. For these
`patients, the probabilities of relapse at 1, 3 and 6 months
`after methotrexate withdrawal were 39, 80 and 90%,
`respectively (Figure 4).
`
`Specific therapeutic goals
`
`The overall success rate for achieving specific therapeutic
`goals for the patients in the present series was 67%. The
`rates for each goal are given in Table 1.
`
`rhis- - (cid:9)
`
`
`
`Ex. 1083 - Page 8
`
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`(cid:9)
`

`

`Table 2. Adverse events in patients treated with methotrexate
`
`No. of
`events
`(0/0)
`
`10 (26)
`
`5
`3
`7 (18)
`5 (13)
`2 (5)
`2 (5)
`2 (5)
`1
`1
`2 (5)
`1 (3)
`1 (3)
`22 (56)*
`
`Methotrexate
`withdrawal
`(no. of
`patients)
`
`3
`
`0
`1
`1
`0
`0
`1
`0
`
`0
`0
`0
`4
`
`Gastrointestinal symptoms
`nausea and vomiting
`diarrhoea
`abdominal pain
`Abnormal liver function tests
`Headache, dizziness
`Fatigue
`Skin rash
`Infections
`herpes zoster
`candidiasis
`Gynaecomastia
`Leukopenia ( < 3000/mL)
`Cough
`Total
`
`* Number (%) of patients with at least one adverse event.
`
`close to those reported by Kozarek et al.' in 14 patients
`(78%) and by Baron et al.' in 10 patients (80 %). In the
`placebo-controlled North American trial,' the percentage
`of improvement was not stated, but the proportion of
`patients in complete remission after 16 weeks of treat-
`ment was 39 %. However, in the latter study, clinical
`remission was defined both as a drop in the Crohn's
`Disease Activity Index to below the threshold of 150 and
`as the complete cessation of corticosteroids. In our series,
`seven of the 24 (29 %) cortico-dependent or cortico-
`resistant patients stopped taking steroids after 4 months
`on methotrexate. In Kozarek et al.'s series,' 30% of
`patients had stopped taking steroids after 12 weeks on
`methotrexate, and in Baron et al.'s series,' the rate was
`20% after 18 weeks.
`In our study, 42 % of patients on maintenance metho-
`trexate treatment were still in remission after 1 year.
`These results are less favourable than those reported by
`Kozarek et al.,' who stated that 51 % of their patients
`taking methotrexate were still in remission after a mean
`follow-up of 69 weeks. In the randomized study by Arora
`et al.,' who compared the results of 15 mg per week of
`oral methotrexate for 1 year with those for a placebo, the
`proportion of patients maintained in remission was 54%
`in the methotrexate group compared with 20% in the
`placebo group (P < 0.05). However, 23% of their
`patients had stopped taking methotrexate because of
`side-effects, so that only 31 % were in fact still in
`
`(C.) 1996 Blackwell Science Ltd, Aliment Pliarinncol Ther 10, 309-314
`
`METHOTREXATE IN CROHN'S DISEASE 313
`
`remission after 1 year of treatment. Taken together, the
`long-term results for methotrexate in Crohn's disease
`therefore seems less favourable than those reported for
`azathioprine'" or 6-mercaptopurine." It is possible
`that the scheme of treatment proposed by Kozarek et al.,'
`and used in our patients, was not sufficient to prevent
`relapse, because it involved both passing from intra-
`muscular to oral administration of the drug after 3
`months, and tapering of the doses. In our patients, the
`mean dose for methotrexate at the time of relapse was
`comparable to those at the time of the last visit of patients
`who did not have a relapse. On the other hand, 90% of
`patients who did have relapse were taking methotrexate
`orally, compared to only 61 % of those who had no
`relapse. This result suggests that the efficacy of metho-
`trexate could be influenced by the route of admini-
`stration of the drug.
`Side-effects were often observed amongst our patients
`during methotrexate treatment, but they were mostly
`moderate, and the treatment had to be stopped in only
`10% of the patients. This proportion is smaller than those
`reported in previous studies.3• 6 None of our patients were
`given supplements of folic acid, which has been shown to
`reduce methotrexate toxicity without affecting its efficacy
`in rheumatoid arthritis.' There was no case of hyper-
`sensitivity pneumopathy in our series, and only one
`patient develo

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket